About RNA 3'-terminal phosphate cyclase-like protein
RNA 3'-terminal phosphate cyclase-like protein (RCL1) is a protein
from Homo sapiens identified by UniProt accession
Q9Y2P8, 373 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | RNA 3'-terminal phosphate cyclase-like protein |
| UniProt accession | Q9Y2P8 |
| Gene | RCL1 |
| Organism | Homo sapiens |
| Length | 373 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (71)
Diseases linked to this target (Open Targets).
- platelet count · score 0.42
- mean corpuscular volume · score 0.41
- mean corpuscular hemoglobin · score 0.41
- platelet crit · score 0.40
- erythrocyte count · score 0.40
- Red cell distribution width · score 0.39
- mean corpuscular hemoglobin concentration · score 0.38
- eosinophil count · score 0.36
- red blood cell density measurement · score 0.35
- reticulocyte count · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y2P8-F1 | alphafold | PREDICTED | 93.11 | — |
Amino-acid sequence (373 residues)
MATQAHSLSY AGCNFLRQRL VLSTLSGRPV KIRKIRARDD NPGLRDFEAS FIRLLDKITN GSRIEINQTG TTLYYQPGLL YGGSVEHDCS VLRGIGYYLE SLLCLAPFMK HPLKIVLRGV TNDQVDPSVD VLKATALPLL KQFGIDGESF ELKIVRRGMP PGGGGEVVFS CPVRKVLKPI QLTDPGKIKR IRGMAYSVRV SPQMANRIVD SARSILNKFI PDIYIYTDHM KGVNSGKSPG FGLSLVAETT SGTFLSAELA SNPQGQGAAV LPEDLGRNCA RLLLEEIYRG GCVDSTNQSL ALLLMTLGQQ DVSKVLLGPL SPYTIEFLRH LKSFFQIMFK IETKPCGEEL KGGDKVLMTC VGIGFSNLSK TLK
Explore RNA 3'-terminal phosphate cyclase-like protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets